Stayble Therapeutics has now initiated the first clinic in Spain for its clinical phase IIb study with the drug candidate STA363 for chronic disc-related low back pain. Thus, the study is underway in all prospective study countries – the Netherlands, Russia and Spain. BioStock has contacted Andreas Gerward, CEO of Stayble Therapeutics, to hear his thoughts on the announcement.
Read the full article at biostock.se:
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se